Mario Gabelli Zentalis Pharmaceuticals, Inc. Transaction History

Gamco Investors, Inc. Et Al

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2022 May 13, 2022	SELL	$41.58 - $80.89 $2.61 Million - $5.07 Million	-62,711 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$35.69 - $52.72 $2.24 Million - $3.31 Million	62,711 New	62,711 $2.72 Million

142

76.3M

68.2K

2.3K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $233M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.